GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 207 filers reported holding GENMAB A/S in Q1 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,255 | -11.9% | 6,018 | -5.1% | 0.00% | -33.3% |
| Q2 2023 | $240,983 | +0.5% | 6,340 | -0.2% | 0.00% | 0.0% |
| Q1 2023 | $239,776 | +93198.1% | 6,350 | +4.8% | 0.00% | 0.0% |
| Q4 2022 | $257 | -99.9% | 6,060 | -13.2% | 0.00% | 0.0% |
| Q2 2022 | $227,000 | -33.0% | 6,980 | -25.4% | 0.00% | -25.0% |
| Q1 2022 | $339,000 | -14.8% | 9,360 | -6.9% | 0.00% | -20.0% |
| Q4 2021 | $398,000 | -10.4% | 10,050 | -1.0% | 0.01% | 0.0% |
| Q3 2021 | $444,000 | +9.6% | 10,150 | +2.4% | 0.01% | 0.0% |
| Q2 2021 | $405,000 | +28.6% | 9,910 | +3.2% | 0.01% | +25.0% |
| Q1 2021 | $315,000 | +10.1% | 9,600 | +36.4% | 0.00% | 0.0% |
| Q4 2020 | $286,000 | +13.0% | 7,040 | +2.0% | 0.00% | 0.0% |
| Q3 2020 | $253,000 | +11.0% | 6,900 | +2.5% | 0.00% | 0.0% |
| Q2 2020 | $228,000 | – | 6,730 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |